The table below shows ALNYLAM PHARMACEUTICALS, INC.'s cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
Line item
FY 2025
FY 2024
FY 2023
FY 2022
FY 2021
FY 2020
Operating cash flow
$524.08M
-$8.31M
$104.16M
-$541.27M
-$641.69M
-$614.96M
Capital expenditure
$58.70M
$34.28M
$62.21M
$72.06M
$76.37M
$70.36M
Investing cash flow
$436.33M
-$116.84M
-$336.35M
$169.35M
-$273.30M
-$435.52M
Dividends paid
-
-
-
-
-
ALNY operating cash flow (10-K history)
ALNYLAM PHARMACEUTICALS, INC. reported operating cash flow of $524.08M for fiscal year 2025. That is up 6405.1% from -$8.31M in fiscal 2024. Over the 10 fiscal years shown, operating cash flow grew from -$307.70M (FY 2016) to $524.08M. Figures come from the company's audited annual reports as filed with the SEC.
